Sodium salts

Method NaCl 1 g tablets have OTC electrolyte-replenisher Drug Facts for physician-directed prevention of perspiration-related heat cramps and preparation of a labeled salt solution. Unity bicarbonate 650 mg tablets are OTC antacids for acid indigestion, heartburn, sour stomach and associated upset stomach. These labels do not establish a self-directed chronic hyponatremia, CKD acidosis or dietary-supplement regimen.

Baxter 0.9% NaCl provides water/electrolytes and hemodialysis priming. Selected 23.4% NaCl is a parenteral-fluid additive requiring dilution. Amneal bicarbonate 150 mEq/L treats clinically significant metabolic acidosis and alkalinizes urine in eligible drug poisonings in adults/children; it must not be used where rapid bicarbonate administration is required, such as cardiac arrest. Hypertonic 3%/5% saline, emergency undiluted 23.4% protocols, bicarbonate 4.2%/8.4% ampules and other sodium salts are excluded.

0.9% contains 9 g/L NaCl, sodium 154 mEq/L and chloride 154 mEq/L; dose/volume/rate depend on age, weight, clinical status and concurrent treatment. 23.4% concentrate contains 234 mg/mL NaCl, 4 mEq/mL each sodium/chloride; prescribed mEq divided by four gives concentrate mL. Aseptic addition to an appropriate IV fluid and dilution are mandatory. This is not an emergency bolus or sodium-correction algorithm.

The NaCl tablet label calls one tablet dissolved in 120 mL an isotonic solution; that recipe is not a verified sterile IV fluid and is not substituted for labeled 0.9% injection. The bicarbonate antacid warning’s age wording overlaps at sixty, while directions explicitly put sixty-and-older at the twelve-tablet limit. Follow the latter stated group; no pediatric antacid dose is provided. The infusion label does not supply a universal poisoning target or correction-rate algorithm.

Selected 0.9% NaCl lists none known but separately directs avoidance/monitoring in fluid overload, sodium disorders and severe renal impairment. Selected 23.4% label’s contraindications section restricts postoperative salt use unless depletion exists; it is not the formal hypernatremia list from a different manufacturer. Selected bicarbonate infusion contraindicates chloride loss from vomiting/continuous GI suction and diuretics producing hypochloremic alkalosis. OTC labels use professional-consultation restrictions; do not invent a class-wide contraindication.

None of the selected labels has a boxed warning. Potentially fatal concentration/route errors and electrolyte or volume complications still require meticulous product selection.

IV NaCl reports include infusion reactions, local burning/rash, sodium disturbances, hyperchloremic metabolic acidosis and hyponatremic encephalopathy. Excess concentrate can cause edema and cardiac-like congestion. Bicarbonate infusion reports sodium-retention edema, electrolyte imbalances and extravasation injury. OTC Drug Facts do not provide a quantified adverse-reaction table; rates are not inferred across products.

Corticosteroids/corticotropin and other sodium-retaining medicines can increase overload. Diuretics and selected antiepileptic/psychotropic medicines may increase hyponatremia risk. The Baxter label contains both increased and decreased lithium-clearance statements; monitor lithium and do not predict a single direction from this internally inconsistent text.

Bicarbonate antacid Drug Facts require pharmacist/doctor review with prescription drugs because interactions are possible; no universal spacing table is provided. Urinary alkalinization intentionally changes elimination of selected poisons under clinical management. IV additives require verified compatibility/stability; the selected bicarbonate infusion uses a dedicated line. Other drugs’ sodium salt names do not imply interchangeability.

OTC products direct consultation before use in pregnancy/breastfeeding. NaCl IV labels have limited formal pregnancy/milk information and benefit/risk or caution wording. The current bicarbonate infusion label summarizes decades of use without an identified developmental-risk signal, but has no milk/infant outcome data; physiological replacement does not justify uncontrolled sodium administration.

Bicarbonate infusion has pediatric indications and the distinct under-two-year regimen above. Rapid administration can cause CNS complications; excessive dilute-product volume may require another product selected by the clinician. Selected NaCl concentrate pediatric safety/effectiveness is unestablished; 0.9% pediatric use rests on clinical practice with close electrolyte monitoring, especially neonates. OTC labels provide no pediatric dosing table. Older adults need cautious selection and renal/electrolyte monitoring.

Impaired sodium excretion increases toxicity/overload risk; Baxter 0.9% directs avoidance in severe renal impairment where possible and monitoring if unavoidable. Bicarbonate infusion calls for monitoring sodium-sensitive kidney disease/anuria, hypertension and failure. Cirrhosis and other hepatic sodium-retention states can increase overload. No universal creatinine-clearance adjustment applies to these five distinct products.

NaCl supplies sodium/chloride and, as an IV fluid, water. Bicarbonate buffers hydrogen ions and raises plasma pH; urinary alkalinization can enhance elimination of particular drugs. Oral bicarbonate has the selected antacid role rather than a universal systemic regimen.

Kidney regulation of sodium/water and bicarbonate is central to exposure effects. Bicarbonate can become carbonic acid and then CO2 exhaled through the lungs; renal and respiratory status matter to acid-base management. A conventional single drug half-life or mg-for-mg conversion is not established for this umbrella entry.

Review exact product concentration, prescribed mEq versus salt mass, pump rate and dilution status. Follow weight/fluid balance, sodium/chloride, potassium and acid-base status as appropriate; monitor renal function and infusion site. Report breathing difficulty, edema, confusion/seizures, muscle twitching or infusion-site pain promptly. OTC use needs review of sodium restriction and all medicines; seek assessment if cramps persist over twenty-four hours or antacid symptoms over two weeks.

Seek medical/Poison Control assessment for overdose or a wrong concentration/route. Clinicians must manage sodium, volume and alkalosis abnormalities individually; no home reversal or safe toxic threshold is supplied. Never make an IV product from tablets. For VIAFLO, do not connect bags in series, pressurize or use an open vent; follow its dedicated-line and sterile-container instructions.

Oral NaCl

Method 1 g white round M119 · NDC 58657-119-01, 100 tablets

Oral bicarbonate

Unity 650 mg antacid · NDC 84275-503-10, 1,000 tablets

NaCl IV examples

Baxter 0.9% VIAFLO; Henry Schein 23.4% 120 mEq / 30 mL single-dose vial

Bicarbonate IV

Amneal 150 mEq / 1,000 mL pouch bag · NDC 80830-2613-1

Selected oral NaCl is 1 g salt with 394 mg sodium; it has no inactive ingredients. Selected bicarbonate tablet is 650 mg salt, 178 mg sodium. NaCl 0.9% is 9 mg/mL; 23.4% is 234 mg/mL and requires dilution. Selected bicarbonate 1.26% is 12.6 mg/mL, 0.15 mEq/mL each sodium/bicarbonate, ready to infuse. Other strengths/routes and all other sodium salts are excluded.

Oral products: 15–30°C; bicarbonate in a well-closed container. Selected 23.4%: 20–25°C, preservative-free, discard unused portion. VIAFLO: room temperature 25°C, avoid excessive heat; inspect seal/clarity/leaks and discard unused fluid or additive mixture. Bicarbonate bag: 20–25°C, excursions 15–30°C; avoid heat/freezing, retain pouch until use and use within twenty-four hours after removal, discarding unused portion. Product-specific instructions must not be generalized.